A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab
نویسندگان
چکیده
منابع مشابه
FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer.
Introduction In Cuba, colorectal cancer (CRC) is the malignant neoplasm with the fourth-highest incidence and third-highest mortality. Over one-third of CRC patients exhibit metastatic disease at the time of diagnosis. Standard treatment for metastatic CRC is a 5-fluorouracil (5-FU) + Folinic Acid (FA) continuous infusion regimen. International studies have shown, however, that systemic therapy...
متن کاملComplete response of liver metastatic gastric cancer after FOLFOX-4 chemotherapy regimen followed by salvage gastrectomy: A case report
A 48-year-old Thai male with metastatic liver gastric adenocarcinoma achieved a complete pathological response after neoadjuvant chemotherapy. The patient underwent a esophagogastroduodenoscopy in October, 2008, which revealed a ten centimeter ulcerated tumor mass at his antrum with complete gastric outlet obstruction. The biopsy of his gastric ulcer showed high grade necrotic adenocarcinoma. F...
متن کاملCapecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
BACKGROUND To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy. PATIENTS AND METHODS A total of 627 patients were randomly assigned to receive XELOX (n = 313) or FOLFOX-4 (n = 314) following disease ...
متن کاملEfficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer.
PURPOSE To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. METHODS IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were alsï given irinïtecan and/ïr ïxaliplatin cïmbined...
متن کاملOral β-Glucan for Mucositis and Leukopenia in Colorectal Cancer Patients Receiving Adjuvant FOLFOX-4
A significant proportion of cancer patients receive complementary medical/herbal therapy while undergoing conventional anti-cancer treatment (McEachrane-Gross et al., 2006; Inglin et al., 2008; Mueller et al., 2008; Yang et al., 2008; Supoken et al., 2009; Nazik et al., 2011). β-glucans (1,3-1,6 β-D-glucan) were recently reported to be one of the active ingredients responsible for the immunomod...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2015
ISSN: 0923-7534
DOI: 10.1093/annonc/mdv335.03